Univariate logistic regressions
| QFT-GIT positive | QFT-Plus positive | TB2−TB1 >0.6 | ||||
| OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | |
| Age | 1.02 (1.00–1.05) | 0.09 | 1.02 (1.00–1.05) | 0.101 | 1.03 (1.00–1.07) | 0.053 |
| Sex | ||||||
| Male | 1 | 1 | 1 | |||
| Female | 0.73 (0.35–1.5) | 0.387 | 0.76 (0.37–1.57) | 0.458 | 1.49 (0.55–4.10) | 0.435 |
| Estimated incidence of TB per 100 000 person-years in country of birth# | ||||||
| 0–50 | 1 | 1 | 1 | |||
| >50 | 1.44 (0.69–3.01) | 0.333 | 1.63 (0.78–3.42) | 0.197 | 0.82 (0.30–2.25) | 0.7 |
| Country of birth | ||||||
| Non-European | 1 | 1 | 1 | |||
| European | 0.84(0.41–1.73) | 0.635 | 0.74 (0.36–1.54) | 0.428 | 3.24 (1.07–9.75) | 0.037 |
| BCG vaccination | ||||||
| No | 1 | 1 | 1 | |||
| Yes | 2.04 (0.75–5.53) | 0.161 | 2.26 (0.87–5.89) | 0.096 | 0.98 (0.25–3.87) | 0.978 |
| Smear status of index case | ||||||
| Negative | 1 | 1 | 1 | |||
| Positive | 1.12 (0.51–2.47) | 0.780 | 1.39 (0.63–3.07) | 0.413 | 1.29 (0.41–4.03) | 0.662 |
| Time spent with the index case h per day | ||||||
| 1–4 | 1 | 1 | 1 | |||
| 5–8 | 1.65 (0.48–5.67) | 0.429 | 3.23 (0.97–10.72) | 0.055 | 3.55 (0.34–36.53) | 0.288 |
| 9–12 | 2.8 (0.57–13.83) | 0.206 | 4.37 (0.89–21.61) | 0.070 | 7.43 (0.59–94.26) | 0.122 |
| >12 | 6.78 (2.28–20.16) | 0.0006 | 14.78(4.62–47.25) | 5.6e-06 | 7.03 (0.85–58.2) | 0.071 |
| Sleeping proximity to the index case | ||||||
| Different house | 1 | 1 | 1 | |||
| Different rooms | 3.79 (1.29–11.14) | 0.015 | 5.78 (1.71–19.52) | 0.005 | 0.51 (0.06–4.52) | 0.545 |
| Same room | 3.98 (1.55–10.23) | 0.004 | 5.65 (2.00–15.97) | 0.001 | 4.34 (1.37–13.81) | 0.013 |
| Immunocompromised | ||||||
| No | 1 | 1 | 1 | |||
| Yes | 0.62 (0.17–2.22) | 0.459 | 1.35 (0.37–4.88) | 0.649 | 0.54 (0.06–4.46) | 0.563 |
QFT-GIT: QuantiFERON-TB Gold in Tube; QFT-Plus: QuantiFERON-TB Plus; TB: tuberculosis; BCG: bacille Calmette-Guerin. #: as per World Health Organization report 2014 [29].